Chemotherapy's effect on overall survival seems to increase based on tumor size

May 15, 2012

The most recent research released in June's Journal of Thoracic Oncology indicates there might be a positive correlation between tumor size and adjuvant platinum based chemotherapy in surgically resected patients with node negative non-small cell lung cancer. The study, published in the June 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, analyzed the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum based chemotherapy in patients with node negative non-small cell lung cancer.

The purpose of the retrospective study was to apply the most current, 7th edition, TNM , to a retrospective cohort of surgically resected, node negative, non-small cell who were treated with adjuvant platinum based chemotherapy. Previous clinical trials confirmed a for adjuvant platinum based chemotherapy for patients with stage II-IIIa non-small cell lung cancer. In addition, the authors explored the interaction between and KRAS mutations in predicting a benefit from the chemotherapy.

After analyzing data from 461 patients that were part of two previous adjuvant trials, JBR.10 and CALBG 9633, the authors found a positive correlation between the size of the tumor and efficacy of chemotherapy with respect to disease free survival. There was no clear demarcation of what T size threshold correlated with benefit of chemotherapy. KRAS mutation was detected in 27 percent of the specimens, correlated with a worse prognosis but not with the size of the tumor.

"Thus, our study reinforces the pressing need for improved understanding of the impact of the new T-size descriptors on adjuvant chemotherapy effect," the authors say. "This is particularly valid when we consider that up to 77 percent of surveyed lung cancer physicians would alter patient management in response to a change in stage designation."

Related Stories

Adjuvant therapy shows promise in biliary tract cancer

April 27, 2012

(HealthDay) -- For patients with biliary tract cancers, postresection adjuvant therapy with chemotherapy or chemoradiotherapy appears to be beneficial in treating patients with biliary tract cancers, with significant improvement ...

Recommended for you

Study reveals new insight into DNA repair

August 3, 2015

DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy. New information published this week reveals more about why this occurs and how these breaks ...

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.